End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12,890 ARS | +2.77% | +10.48% | +38.11% |
May. 22 | Sandoz: Marketing authorization for Wyost and Jubbonti in the EU | CF |
May. 22 | Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 38.91 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+38.11% | 166B | - | ||
+39.54% | 723B | C+ | ||
+34.28% | 595B | B | ||
-3.59% | 369B | C+ | ||
+20.48% | 332B | B- | ||
+2.82% | 282B | C+ | ||
+17.17% | 244B | B+ | ||
+9.16% | 208B | B- | ||
-5.07% | 205B | A+ | ||
+0.09% | 168B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AMGN Stock
- AMGN Stock
- Ratings Amgen Inc.